ALSO NOTED: Companies compete for microdosing tests; Bayer to expand facility; and much more...

> Two small U.S. companies are competing to make the first tests that will register results for newly-allowed microdosing trials. Under new FDA rules, drug developers can test tiny amounts of experimental therapies in humans to get some insight into efficacy before launching expensive studies. The potential specialized drug testing market for microdosing is estimated at $500 million. Report [1]

> Bayer is embarking on a $100 million expansion of its East Walpole, MA facility. Report [2]

> Bayer and Onyx have received the FDA's fast-track status for Nexavar, an experimental therapy for liver cancer. Shares of Onyx were buoyed by the news. Report [3]

> The FDA has fast-tracked Genitope's MyVax cancer treatment. Report [4]

> The FDA has granted a priority review of Amgen's panitumumab for patients with metastaic colorectal cancer. Report [5]

> GlaxoSmithKline's Wellbutrin XL has been approved for seasonal depression. Report [6]

> Beginning in July, Japan's Takeda will deploy its U.S. sales force to co-promote Cephalon's Provigil for sleep disorder. Report [7]

> Chutes & Ladders: Germany's DeveloGen says its CEO, Dr. Guenther Karmann, will leave the company by mutual agreement. Release [8]

> Galapagos will buy the drug discovery service operations of Discovery Partners International for $5.4 million. Report [9]

> The CEO of Belgium's giant UCB told shareholders that the company is exploring "targeted acquisitions." Report [10]

> N-Gene has released positive Phase II data for BGP-15, an insulin sensitizer. Release [11]

> Rigel has received $1 million in milestone payments from Merck. Release [12]

And Finally… A new study shows that people are generally successful at matching the pictures of drivers with their cars, showing that most people typically project a public profile that is easily recognizable by others. Article [13]